Rexahn Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing best-in-class therapeutics for the treatment of cancer. The company also has developed proprietary drug discovery platform technologies in the areas of Nano-Polymer-Drug Conjugate Systems (NPDCS), nano-medicines, 3D-GOLD, and TIMES.

The company reported today that it has signed an exclusive license agreement with the University of Maryland, Baltimore, for its NPDCS platform. It is a result of initial funding through a Maryland Industrial Partnership (MIPS) award. The awards are intended to foster relationships between Maryland universities and industries.

This particular technology targets the delivery of currently marketed chemotherapeutic agents directly into cancerous tumors. Rexahn’s NPDCS platform combines existing chemotherapeutic agents with a proprietary polymer carrier that contains a signaling component.

This approach reduces the levels of anti-cancer agents circulating in the body, which substantially lowers the risk possible adverse side effects while maximizing anti-tumor activity. Rexahn’s delivery method has been shown to result in increased efficacy and reduced toxicity and beats other current delivery methods.

For additional information about Rexahn Pharmaceuticals, please visit www.rexahn.com

Let us hear your thoughts below: